{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T20:03:19Z","timestamp":1727121799336},"reference-count":16,"publisher":"Bentham Science Publishers Ltd.","issue":"23","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p\/>\n<\/jats:sec>","DOI":"10.2174\/0113816128300373240514072201","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T11:51:46Z","timestamp":1716378706000},"page":"1787-1790","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Biologic Therapies in Chronic Prurigo: The Evolving Landscape of\nChronic Prurigo Treatment"],"prefix":"10.2174","volume":"30","author":[{"given":"Aleksandra A.","family":"Stefaniak","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/exd.13972","volume":"28","author":"Pereira M.P.","year":"2019","unstructured":"Pereira M.P.; St\u00e4nder S.; How to define chronic prurigo? Exp Dermatol  2019,28(12),1455-1460","journal-title":"Exp Dermatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1097\/itx.0000000000000042","volume":"5","author":"St\u00e4nder S.","year":"2020","unstructured":"St\u00e4nder S.; Pereira M.P.; Berger T.; IFSI-guideline on chronic prurigo including prurigo nodularis. Itch  2020,5(4),e42-e2","journal-title":"Itch"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/ITT.S316602","volume":"11","author":"Labib A.","year":"2022","unstructured":"Labib A.; Ju T.; Vander Does A.; Yosipovitch G.; Immunotargets and therapy for prurigo nodularis. ImmunoTargets Ther  2022,11,11-21","journal-title":"ImmunoTargets Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/exd.14034","volume":"28","author":"Campion M.","year":"2019","unstructured":"Campion M.; Smith L.; Gatault S.; M\u00e9tais C.; Buddenkotte J.; Steinhoff M.; Interleukin\u20104 and interleukin\u201013 evoke scratching behaviour in mice. Exp Dermatol  2019,28(12),1501-1504","journal-title":"Exp Dermatol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40257-023-00818-z","volume":"25","author":"M\u00fcller S.","year":"2024","unstructured":"M\u00fcller S.; Zeidler C.; St\u00e4nder S.; Chronic prurigo including prurigo nodularis: New insights and treatments. Am J Clin Dermatol  2024,25(1),15-33","journal-title":"Am J Clin Dermatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"Oetjen L.K.","year":"2017","unstructured":"Oetjen L.K.; Mack M.R.; Feng J.; Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell  2017,171(1),217-228.e13","journal-title":"Cell"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"Yosipovitch G.","year":"2023","unstructured":"Yosipovitch G.; Mollanazar N.; St\u00e4nder S.; Dupilumab in patients with prurigo nodularis: Two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med  2023,29(5),1180-1190","journal-title":"Nat Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1159\/000529965","volume":"239","author":"Gao Z.","year":"2023","unstructured":"Gao Z.; Dou Y.; Zhao P.; Wang C.J.; Zhang J.; Successful treatment of prurigo nodularis by dupilumab: Report of 24 patients. Dermatology  2023,239(4),658-663","journal-title":"Dermatology"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/1346-8138.16803","volume":"50","author":"Fang H.Y.","year":"2023","unstructured":"Fang H.Y.; Lian C.H.; The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real\u2010life observational study. J Dermatol  2023,50(8),1084-1087","journal-title":"J Dermatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1080\/09546634.2020.1853024","volume":"33","author":"Husein-ElAhmed H.","year":"2022","unstructured":"Husein-ElAhmed H.; Steinhoff M.; Dupilumab in prurigo nodularis: A systematic review of current evidence and analysis of predictive factors to response. J Dermatolog Treat  2022,33(3),1547-1553","journal-title":"J Dermatolog Treat"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.abd.2022.09.008","volume":"98","author":"Zhang Z.","year":"2023","unstructured":"Zhang Z.; Li S.; Wang Y.; Zhao J.; A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis. An Bras Dermatol  2023,98(4),440-448","journal-title":"An Bras Dermatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","volume":"382","author":"St\u00e4nder S.","year":"2020","unstructured":"St\u00e4nder S.; Yosipovitch G.; Legat F.J.; Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med  2020,382(8),706-716","journal-title":"N Engl J Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/jdv.18377","volume":"36","author":"St\u00e4nder S.","year":"2022","unstructured":"St\u00e4nder S.; Yosipovitch G.; Lacour J.P.; Nemolizumab efficacy in prurigo nodularis: Onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol  2022,36(10),1820-1825","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","volume":"389","author":"Kwatra S.G.","year":"2023","unstructured":"Kwatra S.G.; Yosipovitch G.; Legat F.J.; Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med  2023,389(17),1579-1589","journal-title":"N Engl J Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"101826","DOI":"10.1016\/j.eclinm.2023.101826","volume":"57","author":"Sofen H.","year":"2023","unstructured":"Sofen H.; Bissonnette R.; Yosipovitch G.; Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: A randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine  2023,57,101826","journal-title":"EClinicalMedicine"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1056\/NEJMc2016395","volume":"383","author":"Bernstein J.A.","year":"2020","unstructured":"Bernstein J.A.; Singh U.; Rao M.B.; Berendts K.; Zhang X.; Mutasim D.; Benralizumab for chronic spontaneous urticaria. N Engl J Med  2020,383(14),1389-1391","journal-title":"N Engl J Med"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113816128300373240514072201","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/230196\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113816128300373240514072201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T12:02:05Z","timestamp":1726488125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/230196\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":16,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113816128300373240514072201","relation":{},"ISSN":["1381-6128"],"issn-type":[{"type":"print","value":"1381-6128"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}